- Home
- SNBR vs XOMA Comparison
SNBR vs XOMA Comparison
Compare SNBR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- XOMA
- Stock Information
- Founded
- SNBR 1987
- XOMA 1981
- Country
- SNBR United States
- XOMA United States
- Employees
- SNBR N/A
- XOMA N/A
- Industry
- SNBR Home Furnishings
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- SNBR Consumer Discretionary
- XOMA Health Care
- Exchange
- SNBR Nasdaq
- XOMA Nasdaq
- Market Cap
- SNBR N/A
- XOMA 320.8M
- IPO Year
- SNBR 1998
- XOMA N/A
- Fundamental
- Price
- SNBR $14.46
- XOMA $28.59
- Analyst Decision
- SNBR Hold
- XOMA Strong Buy
- Analyst Count
- SNBR 3
- XOMA 2
- Target Price
- SNBR $14.17
- XOMA $78.50
- AVG Volume (30 Days)
- SNBR 331.0K
- XOMA 18.9K
- Earning Date
- SNBR 10-30-2024
- XOMA 11-05-2024
- Dividend Yield
- SNBR N/A
- XOMA N/A
- EPS Growth
- SNBR N/A
- XOMA N/A
- EPS
- SNBR N/A
- XOMA N/A
- Revenue
- SNBR $1,781,028,000.00
- XOMA $15,239,000.00
- Revenue This Year
- SNBR N/A
- XOMA $456.45
- Revenue Next Year
- SNBR $2.90
- XOMA $29.84
- P/E Ratio
- SNBR N/A
- XOMA N/A
- Revenue Growth
- SNBR N/A
- XOMA 277.95
- 52 Week Low
- SNBR $8.13
- XOMA $14.27
- 52 Week High
- SNBR $21.96
- XOMA $30.50
- Technical
- Relative Strength Index (RSI)
- SNBR 42.68
- XOMA 53.55
- Support Level
- SNBR $14.08
- XOMA $28.66
- Resistance Level
- SNBR $17.08
- XOMA $30.50
- Average True Range (ATR)
- SNBR 1.09
- XOMA 1.07
- MACD
- SNBR -0.29
- XOMA 0.21
- Stochastic Oscillator
- SNBR 14.73
- XOMA 55.56
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.